Exploring the effects of entecavir treatment on the degree of liver fibrosis in patients with non-alcoholic fatty liver combined with chronic hepatitis B in Tibet region

• Published in: Zhonghua gan zang bing za zhi Vol. 30; no. 3; p. 304
• Main Authors: Wen, Q P, Qian, H, Ba, S, Lu, M J, Silang, L D J, Shi, L
• Format: Journal Article
• Language: Chinese
• Published: China 20-03-2022
• Subjects: Antiviral Agents - therapeutic use; DNA, Viral; Guanine - analogs & derivatives; Hepatitis B e Antigens; Hepatitis B, Chronic - complications; Hepatitis B, Chronic - drug therapy; Humans; Liver Cirrhosis - complications; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - drug therapy; Retrospective Studies; Tibet; Treatment Outcome; Tibet
• ISSN: 1007-3418
• DOI: 10.3760/cma.j.cn501113-20200628-00347

To explore the efficacy of entecavir antiviral therapy on the degree of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) combined with chronic hepatitis B (CHB) in Tibet region.
HBeAg-positive CHB patients who were treated with entecavir in the outpatient and inpatient Department of Infectious Diseases of the Tibet Autonomous Region people's Hospital between January 2018 to December 2019 were retrospectively analyzed. Among the 140 subjects with CHB, 95 cases were CHB alone, and the other 45 cases were diagnosed as CHB combined with NAFLD by ultrasound. All patients were given entecavir 0.5 mg orally once daily on an empty stomach for 48 weeks. HBeAg negative conversion rate, blood glucose, blood lipid, liver function and the degree of liver fibrosis were compared between the two groups at the 12th, 24th and 48th weeks of treatment to evaluate the virological response. SPSS 19.0 statistical software was used to process the data. Measurement data were expressed as mean ± standard devia